B. Metzler seel. Sohn & Co. Holding AG Invests $923,000 in DaVita Inc. (NYSE:DVA)

B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in DaVita Inc. (NYSE:DVA) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 5,633 shares of the company’s stock, valued at approximately $923,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BOKF NA raised its stake in DaVita by 286,550.0% in the 1st quarter. BOKF NA now owns 5,733 shares of the company’s stock valued at $790,000 after acquiring an additional 5,731 shares during the period. Assenagon Asset Management S.A. raised its stake in DaVita by 29.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock valued at $6,942,000 after acquiring an additional 11,454 shares during the period. Comerica Bank raised its stake in DaVita by 41.4% in the 1st quarter. Comerica Bank now owns 34,431 shares of the company’s stock valued at $4,753,000 after acquiring an additional 10,074 shares during the period. MBB Public Markets I LLC bought a new stake in DaVita in the 2nd quarter valued at about $582,000. Finally, Chase Investment Counsel Corp raised its stake in DaVita by 56.3% in the 3rd quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company’s stock valued at $5,423,000 after acquiring an additional 11,912 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DVA. UBS Group upped their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, DaVita currently has an average rating of “Hold” and an average price target of $161.80.

Insiders Place Their Bets

In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This represents a 36.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at approximately $141,219,407.87. This trade represents a 3.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 156,086 shares of company stock valued at $24,807,161 over the last quarter. 2.00% of the stock is owned by corporate insiders.

DaVita Stock Up 0.8 %

Shares of NYSE DVA opened at $165.51 on Friday. DaVita Inc. has a 12 month low of $98.26 and a 12 month high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm has a market capitalization of $13.57 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 0.93 and a beta of 0.89. The business has a 50-day moving average of $158.31 and a 200-day moving average of $148.36.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.85 EPS. Sell-side analysts expect that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.